Senior Management Change at Bayer Türkiye

André Santiago Silva, who has more than 20 years of experience in the healthcare sector, took up his post as President of the Bayer Pharmaceuticals Türkiye and Iran Country Group as of September 1, 2026. Silva took over the role from Colin Tyrer, who has led Bayer Türkiye's Pharmaceuticals division since 2023.

A leadership change has taken place in the Pharmaceuticals division at Bayer Türkiye. André Santiago Silva was appointed as President of the Bayer Pharmaceuticals Türkiye and Iran Country Group as of September 1, 2026.

In his new role, Silva will be responsible for Bayer's pharmaceutical operations in Türkiye. Continuing his work with a focus on science and innovation, Silva will concentrate on developing collaborations with patients, healthcare professionals, public institutions and industry stakeholders. Silva will also take on the management of Bayer's pharmaceutical operations in Iran.

Silva took over the role from Colin Tyrer, who has been managing Bayer Türkiye's Pharmaceuticals division since 2023. Tyrer, who will retire following his career at Bayer, led an important period in the development of pharmaceutical operations in Türkiye.

More than 20 years of international healthcare sector experience
André Santiago Silva, who completed his undergraduate and graduate studies in pharmacy at the University of Lisbon, has more than 20 years of experience in the healthcare sector.

Throughout his career, Silva has held various roles of responsibility in Portugal, Germany and the Nordic countries, most recently serving as Bayer Country Manager for Denmark and Norway.

In that role, Silva led a significant transformation process at the company, working to develop collaborations within the healthcare ecosystem and to increase patients' access to innovative treatments.

Silva previously served at Bayer as Global Brand Director. In this position, he was responsible for developing global strategies for key products and brands.

"We will continue to create value with our focus on science and innovation"
Commenting on his new role, André Santiago Silva noted that Türkiye is one of Bayer's important markets.

Silva said, "I am very pleased to have joined Bayer Türkiye and to have the opportunity to work with our experienced teams. Türkiye is an important country for Bayer with its strong scientific knowledge base and advanced healthcare ecosystem. In the coming period, we aim to build further on the achievements reached to date and the strong foundation that has been established."

Stating that long-standing relationships and collaborations with healthcare professionals, public institutions and industry stakeholders will be strengthened and continued, Silva said, "In line with our focus on science and innovation, we will continue to create value for patients and the healthcare system. In this process, drawing strength from Bayer Türkiye's deep-rooted experience and the expertise of our teams, I look forward with great anticipation to contributing to the development of healthcare in our country."

About Bayer
Bayer is a global life sciences company operating in the fields of health and nutrition. In line with its mission of "Health for All, Hunger for None," the company aims to offer solutions with its products and services to the problems encountered globally in the fields of health and nutrition.

Operating in line with the principles of sustainable development, Bayer focuses on creating value through innovation and growth.

As of fiscal year 2025, Bayer has approximately 88,000 employees, with sales revenue of EUR 45.6 billion and R&D expenditure at the level of EUR 5.8 billion.